Gera, Roland Gerard

[["dc.bibliographiccitation.artnumber","mds.28738"],["dc.bibliographiccitation.firstpage","2874"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","2887"],["dc.bibliographiccitation.volume","36"],["dc.contributor.affiliation","Schulz, Isabel; 1\r\nParacelsus‐Elena‐Klinik\r\nKassel Germany"],["dc.contributor.affiliation","Kruse, Niels; 2\r\nDepartment of Neuropathology\r\nUniversity Medical Centre Goettingen\r\nGoettingen Germany"],["dc.contributor.affiliation","Gera, Roland G.; 3\r\nDepartment of Medical Statistics\r\nUniversity Medical Centre Goettingen\r\nGoettingen Germany"],["dc.contributor.affiliation","Kremer, Thomas; 4\r\nRoche Pharmaceutical Research and Early Development\r\nNRD Neuroscience and Rare Disease, Roche Innovation Center Basel, F. Hoffmann‐La Roche Ltd\r\nBasel Switzerland"],["dc.contributor.affiliation","Cedarbaum, Jesse; 5\r\nCoeruleus Clinical Sciences LLC\r\nWoodbidge Connecticut USA"],["dc.contributor.affiliation","Barbour, Robin; 7\r\nProthena Biosciences Inc.\r\nSan Francisco California USA"],["dc.contributor.affiliation","Zago, Wagner; 7\r\nProthena Biosciences Inc.\r\nSan Francisco California USA"],["dc.contributor.affiliation","Schade, Sebastian; 8\r\nDepartment of Neurology\r\nUniversity Medical Centre Goettingen\r\nGoettingen Germany"],["dc.contributor.affiliation","Otte, Birgit; 8\r\nDepartment of Neurology\r\nUniversity Medical Centre Goettingen\r\nGoettingen Germany"],["dc.contributor.affiliation","Bartl, Michael; 8\r\nDepartment of Neurology\r\nUniversity Medical Centre Goettingen\r\nGoettingen Germany"],["dc.contributor.affiliation","Hutten, Samantha J.; 9\r\nThe Michael J. Fox Foundation for Parkinson's Research\r\nNew York New York USA"],["dc.contributor.affiliation","Trenkwalder, Claudia; 1\r\nParacelsus‐Elena‐Klinik\r\nKassel Germany"],["dc.contributor.author","Schulz, Isabel"],["dc.contributor.author","Kruse, Niels"],["dc.contributor.author","Gera, Roland G."],["dc.contributor.author","Kremer, Thomas"],["dc.contributor.author","Cedarbaum, Jesse"],["dc.contributor.author","Barbour, Robin"],["dc.contributor.author","Zago, Wagner"],["dc.contributor.author","Schade, Sebastian"],["dc.contributor.author","Otte, Birgit"],["dc.contributor.author","Bartl, Michael"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Hutten, Samantha J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2021-09-01T06:42:14Z"],["dc.date.available","2021-09-01T06:42:14Z"],["dc.date.issued","2021"],["dc.date.updated","2022-03-21T11:31:27Z"],["dc.description.abstract","ABSTRACT Background Objective diagnostic biomarkers are needed to support a clinical diagnosis. Objectives To analyze markers in various neurodegenerative disorders to identify diagnostic biomarker candidates for mainly α‐synuclein (aSyn)‐related disorders (ASRD) in serum and/or cerebrospinal fluid (CSF). Methods Upon initial testing of commercially available kits or published protocols for the quantification of the candidate markers, assays for the following were selected: total and phosphorylated aSyn (pS129aSyn), neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH), tau protein (tau), ubiquitin C‐terminal hydrolase L1 (UCHL‐1), glial fibrillary acidic protein (GFAP), calcium‐binding protein B (S100B), soluble triggering receptor expressed on myeloid cells 2 (sTREM‐2), and chitinase‐3‐like protein 1 (YKL‐40). The cohort comprised participants with Parkinson's disease (PD, n = 151), multiple system atrophy (MSA, n = 17), dementia with Lewy bodies (DLB, n = 45), tau protein‐related neurodegenerative disorders (n = 80, comprising patients with progressive supranuclear palsy (PSP, n = 38), corticobasal syndrome (CBS, n = 16), Alzheimer's disease (AD, n = 11), and frontotemporal degeneration/amyotrophic lateral sclerosis (FTD/ALS, n = 15), as well as healthy controls (HC, n = 20). Receiver operating curves (ROC) with area under the curves (AUC) are given for each marker. Results CSF total aSyn was decreased. NfL, pNfH, UCHL‐1, GFAP, S100B, and sTREM‐2 were increased in patients with neurodegenerative disease versus HC (P < 0.05). As expected, some of the markers were highest in AD (i.e., UCHL‐1, GFAP, S100B, sTREM‐2, YKL‐40). Within ASRD, CSF NfL levels were higher in MSA than PD and DLB (P < 0.05). Comparing PD to HC, interesting serum markers were S100B (AUC: 0.86), sTREM2 (AUC: 0.87), and NfL (AUC: 0.78). CSF S100B and serum GFAP were highest in DLB. Conclusions Levels of most marker candidates tested in serum and CSF significantly differed between disease groups and HC. In the stratification of PD versus other tau‐ or aSyn‐related conditions, CSF NfL levels best discriminated PD and MSA. CSF S100B and serum GFAP best discriminated PD and DLB. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.28738"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89011"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.relation.eissn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1999"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","2008"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Dakna, Mohammed"],["dc.contributor.author","Kruse, Niels"],["dc.contributor.author","Galasko, Douglas"],["dc.contributor.author","Foroud, Tatiana"],["dc.contributor.author","Zetterberg, Henrik"],["dc.contributor.author","Schade, Sebastian"],["dc.contributor.author","Gera, Roland G."],["dc.contributor.author","Wang, Wenting"],["dc.contributor.author","Gao, Feng"],["dc.contributor.author","Frasier, Mark"],["dc.contributor.author","Chahine, Lana M."],["dc.contributor.author","Coffey, Christopher S."],["dc.contributor.author","Singleton, Andrew B."],["dc.contributor.author","Simuni, Tanya"],["dc.contributor.author","Weintraub, Daniel"],["dc.contributor.author","Seibyl, John"],["dc.contributor.author","Toga, Arthur W."],["dc.contributor.author","Tanner, Caroline M."],["dc.contributor.author","Kieburtz, Karl"],["dc.contributor.author","Marek, Kenneth"],["dc.contributor.author","Siderowf, Andrew"],["dc.contributor.author","Cedarbaum, Jesse M."],["dc.contributor.author","Hutten, Samantha J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Graham, Danielle"],["dc.date.accessioned","2021-04-14T08:24:53Z"],["dc.date.available","2021-04-14T08:24:53Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker. Methods We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson's disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson's disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers. Results In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson's disease patients versus controls (P \\u0026lt; 0.01). Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores showed a negative association. Conclusions Neurofilament light chain in serum samples is increased in Parkinson's disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson's disease severity. Although the specificity of neurofilament light chain for Parkinson's disease is low, it is the first blood‐based biomarker candidate that could support disease stratification of Parkinson's disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society."],["dc.description.sponsorship","AbbVie http://dx.doi.org/10.13039/100006483"],["dc.description.sponsorship","Avid Radiopharmaceuticals http://dx.doi.org/10.13039/100014392"],["dc.description.sponsorship","Biogen Idec http://dx.doi.org/10.13039/100006314"],["dc.description.sponsorship","Bristol‐Myers Squibb http://dx.doi.org/10.13039/100002491"],["dc.description.sponsorship","Covance"],["dc.description.sponsorship","Eli Lilly \\u0026 Co"],["dc.description.sponsorship","F. Hoffman‐La Roche, Ltd"],["dc.description.sponsorship","GE Healthcare http://dx.doi.org/10.13039/100006775"],["dc.description.sponsorship","Genentech http://dx.doi.org/10.13039/100004328"],["dc.description.sponsorship","GlaxoSmithKline http://dx.doi.org/10.13039/100004330"],["dc.description.sponsorship","Lundbeck http://dx.doi.org/10.13039/501100013327"],["dc.description.sponsorship","Merck http://dx.doi.org/10.13039/100004334"],["dc.description.sponsorship","MesoScale"],["dc.description.sponsorship","Michael J. Fox Foundation for Parkinson's Research http://dx.doi.org/10.13039/100000864"],["dc.description.sponsorship","Pfizer http://dx.doi.org/10.13039/100004319"],["dc.description.sponsorship","Piramal"],["dc.description.sponsorship","UCB http://dx.doi.org/10.13039/100011110"],["dc.identifier.doi","10.1002/mds.28206"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81454"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","John Wiley \\u0026 Sons, Inc."],["dc.relation.eissn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]